Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Early antibody therapy can induce long-lasting immunity to SHIV.

Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA.

Nature. 2017 Mar 23;543(7646):559-563. doi: 10.1038/nature21435. Epub 2017 Mar 13.


Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y.

J Exp Med. 2014 Sep 22;211(10):2061-74. doi: 10.1084/jem.20132494. Epub 2014 Aug 25.


Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA.

Nature. 2013 Nov 14;503(7475):277-80. doi: 10.1038/nature12746. Epub 2013 Oct 30.


Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.

Sadjadpour R, Donau OK, Shingai M, Buckler-White A, Kao S, Strebel K, Nishimura Y, Martin MA.

J Virol. 2013 Aug;87(15):8798-804. doi: 10.1128/JVI.00878-13. Epub 2013 May 29.


Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Shingai M, Donau OK, Schmidt SD, Gautam R, Plishka RJ, Buckler-White A, Sadjadpour R, Lee WR, LaBranche CC, Montefiori DC, Mascola JR, Nishimura Y, Martin MA.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74. doi: 10.1073/pnas.1217443109. Epub 2012 Nov 5.


Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA.

J Virol. 2012 Aug;86(16):8516-26. doi: 10.1128/JVI.00644-12. Epub 2012 May 30.


Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.

Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD, Geng Y, Wilson IA, Poignard P, Martin MA, Burton DR.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20125-9. doi: 10.1073/pnas.1117531108. Epub 2011 Nov 28.


Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Nishimura Y, Shingai M, Lee WR, Sadjadpour R, Donau OK, Willey R, Brenchley JM, Iyengar R, Buckler-White A, Igarashi T, Martin MA.

J Virol. 2011 Oct;85(20):10617-26. doi: 10.1128/JVI.05010-11. Epub 2011 Aug 3.


Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Goncalvez AP, Chien CH, Tubthong K, Gorshkova I, Roll C, Donau O, Schuck P, Yoksan S, Wang SD, Purcell RH, Lai CJ.

J Virol. 2008 Jul;82(14):7009-21. doi: 10.1128/JVI.00291-08. Epub 2008 May 14.


Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.

Igarashi T, Donau OK, Imamichi H, Nishimura Y, Theodore TS, Iyengar R, Erb C, Buckler-White A, Buckler CE, Martin MA.

J Virol. 2007 Oct;81(19):10669-79. Epub 2007 Jul 11.


Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.

Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA.

Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12324-9. Epub 2004 Aug 5.


Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic.

Sadjadpour R, Theodore TS, Igarashi T, Donau OK, Plishka RJ, Buckler-White A, Martin MA.

J Virol. 2004 May;78(10):5513-9.


Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.

Igarashi T, Donau OK, Imamichi H, Dumaurier MJ, Sadjadpour R, Plishka RJ, Buckler-White A, Buckler C, Suffredini AF, Lane HC, Moore JP, Martin MA.

J Virol. 2003 Dec;77(24):13042-52.


Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15131-6. Epub 2003 Nov 19.


Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Igarashi T, Endo Y, Nishimura Y, Buckler C, Sadjadpour R, Donau OK, Dumaurier MJ, Plishka RJ, Buckler-White A, Martin MA.

J Virol. 2003 Oct;77(20):10829-40.


Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.

Imamichi H, Igarashi T, Imamichi T, Donau OK, Endo Y, Nishimura Y, Willey RL, Suffredini AF, Lane HC, Martin MA.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13813-8. Epub 2002 Oct 7.

Supplemental Content

Support Center